ALK France

Last updated: 26.11.2015

logo

ALK is a global research-driven pharmaceutical company that focuses on prevention, diagnosis and treatment of allergies. Since 1923 ALK has been working to improve the quality of life for allergy patients by developing drugs that target the cause of allergy. ALK is the world leader in allergy immunotherapy – a unique treatment of the cause of allergies. The treatment induces a protective immune response that provides a sustained reduction of allergy symptoms and reduces the risk of developing asthma. ALK provides allergy immunotherapy products as injections, sublingual drops and sublingual tablets, which is the newest, best documented and most convenient treatment for patients. The portfolio of products also includes an adrenaline used to treat severe allergic reactions (anaphylactic shock).

ALK invests annually approximately 20% of revenue in research that aims to develop new, evidence-based allergy immunotherapy.  ALK has signed partnership agreements with Merck and Torii Pharmaceutical, concerning the development, registration and commercialisation of tablets in Northern America and Japan. ALK has approxiately 1,800 employees with subsidiaries, production facilities and distributors worldwide. The company headquarters is in Denmark and is listed on NASDAQ OMX Copenhagen with subsidiaries and associated companies in Austria, China, Denmark, Finland, France, Germany, Italy, the Netherlands, Norway, Poland, Spain, Sweden, Switzerland, the United Kingdom and the USA.

Contact

ALK
55270 Varennes en Argonne Cedex
France

E-mail: f.bayard@alk-abello.com
T (+33) 3 29 80 71 62
F (+33) 3 29 80 24 34
M contact@alk-abello.com

Web: alk-abello.com

Related

We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here